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Introduction: Fluorescent analysis has been widely used in biological, 
chemical and analytical research. A useful fluorescent labeling agent should 
include NIR emission, a large Stoke’s shift, and good labeling ability without 
interfering with the pharmacological profile of the labeled compound. Thus, 
we planned to develop an M-AMF-DOTA(Nd) derivative composed of an NIR 
fluorescent moiety and a maleimide conjugating moiety as a new NIR 
fluorescent labeling agent which fulfills these requirements.  
Methods: M-AMF-DOTA(Nd) was synthesized from 4-amino-fluorescein and 
was conjugated with an avidin molecule (Avidin-AMF-DOTA(Nd)) through 
Lys-side chains by reaction with 2-iminothiolane. The fluorescent features of 
M-AMF-DOTA(Nd) and Avidin-AMF-DOTA(Nd) were comparatively 
evaluated. A binding assay of Avidin-AMF-DOTA(Nd) with D-biotin and a 
tumor cell-uptake study were performed to estimate the effects of 
conjugation on the biological and physicochemical features of the protein.  
Results: M-AMF-DOTA(Nd) was obtained in 22% overall yield. 
M-AMF-DOTA(Nd) had a typical NIR fluorescence from the Nd ion (880 nm 
and 900 nm from 488 nm excitation). Avidin-AMF-DOTA(Nd) was easily 
synthesized and also had typical NIR fluorescence from the Nd ion without 
loss of fluorescent intensity. The binding affinity of Avidin-AMF-DOTA(Nd) 
to D-biotin was equivalent to naive avidin. Avidin-AMF-DOTA(Nd) was 
taken up by tumor cells in the same manner as avidin conjugated with 
fluorescein isothiocyanate, an established, widely used fluorescent avidin. 
Conclusion: Results from this study indicate that M-AMF-DOTA(Nd) is a 
potential labeling agent for routine NIR fluorescent analysis. 
 Introduction 
 
Fluorescent imaging, one of several molecular imaging techniques, is a 
very convenient method because of its simple and safe operation, high 
spatial resolution, and short detection time. Fluorescent labels are widely 
used for applications in biology[1], biotechnology[2], medicine[3], and in 
combinatorial chemistry[4] as encoders of individual library members and as 
reporters of chemical reactions. Fluorescent labeling agents should not 
influence the pharmacological character of a labeled compound. In addition, 
near-infrared (NIR) fluorescence and a large Stoke’s shift are desirable 
characteristics of labeling agents in the fields of biology, biotechnology, and 
medicine since NIR light has good permeability in living organisms and 
there is negligible self-fluorescence in the NIR region. A large Stoke’s shift 
makes it easier to remove scattered and reflected excitation light by suitable 
optical filters. However, there are few agents that possess all of these 
features. Thus, we planned to develop a novel fluorescent labeling agent for 
fluorescent imaging of proteins in living organisms.  
 
We recently reported new NIR fluorescent dyes with low molecular 
weight, 4AMF-DOTA(Nd) (MW = 883)[5] and PAN-DOTA(Yb) (MW = 823)[6], 
which include lanthanide complexes in their structures. They had NIR 
emission and large Stoke’s shifts (880 and 900 nm from 488 nm excitation 
light for 4AMF-DOTA(Nd), 975 nm from 530 nm excitation light for 
PAN-DOTA(Yb)). Their emission wavelengths were constant under various 
conditions (pH and solvents). Therefore, these NIR fluorescent dyes are 
promising candidates for use as fluorescent labeling agents with some 
modification. In this regard, we selected 4AMF-DOTA(Nd) as the starting 
structure of the labeling agent because it has several functional groups 
capable of being modified to bind with a functional molecule and at the 
excitation wavelength it has a stronger absorption and gives a more potent 
signal intensity than PAN-DOTA(Yb).  
 A conjugating moiety was required to link 4AMF-DOTA(Nd) and a 
functional molecule. As a conjugating moiety, maleimide was selected 
because it has very fast reactivity, good selectivity, and makes a very stable 
bond with thiols. Maleimide was linked to one of the DOTA carboxyl groups 
[7], and the remaining carboxyl groups were capped as amides in order to 
avoid changes in fluorescence and chelating ability since carboxyl groups 
often interact with cationic groups and solutes which might alter the 
fluorescence properties of the complex. The selection of a suitable spacer 
between the fluorophore and the conjugation moiety is also important. We 
selected a 6-atom ethyl-propyl amide chain as the spacer because moderately 
inflexible chains composed of 6~12 atoms have been adopted as an 
appropriate length and rigidity to suppress interaction between the labeled 
molecule and the fluorophore, which otherwise could result in altered 
fluorescence as well as chemical and physical properties of the labeled 
molecule [8-12]. 
 
The above analysis led to the design and synthesis of M-AMF-DOTA(Nd) 
that includes a maleimide (Scheme 1) as a new NIR fluorescent labeling 
agent with a large Stoke’s shift. In addition, we have evaluated the imaging 
potential of M-AMF-DOTA(Nd) conjugated to avidin 
(Avidin-AMF-DOTA(Nd)) through binding experiments with biotin and in 
tumor cell-uptake studies.  
 Materials and Methods 
 
Materials  
All chemicals used in this study were commercial products of the highest 
purity and if necessary were further purified by standard methods. Avidin 
and D-biotin were purchased from Nacalai Tesque, Inc. (Kyoto, Japan). 
125I-iodide was purchased from Perkin Elmer Life and Analytical Sciences 
(Boston, MA). C6 glioma cells were purchased from the Health Science 
Research Resources Bank (Tokyo, Japan). 
 
Instruments  
FT-IR spectra were recorded with a Shimadzu, IRAffinity-1 (Shimadzu 
Corporation, Kyoto, Japan). UV-vis spectra were measured using a UV-1800 
(Shimadzu Corporation, Kyoto, Japan). ESI-MS measurements were 
performed on a Shimadzu LC-MS2010 EV (Shimadzu Corporation, Kyoto, 
Japan). 1H-NMR spectra were recorded on a JEOL JNM-AL400 (JEOL Ltd., 
Tokyo, Japan). Fluorescent spectroscopy was performed with a Fluorolog-3 
with a NIR sensitive photomultiplier detection system (~1200 nm) (HORIBA 
Jobin Yvon Inc., Kyoto, Japan). The slit width was 10 nm for both excitation 
and emission measurements. Time-resolved fluorescence spectra were 
recorded on a Fluorolog-3 with Phosphorescence (HORIBA Jobin Yvon Inc., 
Kyoto, Japan). The slit width was 12 nm for both excitation and emission. In 
both fluorescence spectra measurements, the photomultiplier voltage was 
1450 V. Flow cytometry was performed on a FACScan (Becton Dickinson Inc., 
Franklin Lakes, NJ, USA). Radioactivities were counted by Cobra 
Auto-Gamma Counter 5010 (Packard instruments Co., Downers Grove, IL, 
USA). Fluorescent images were photographed with a ChemiDoc XRS 
(Bio-Rad Japan, Tokyo, Japan). 
 
Fluorescence Emission and Excitation Spectral Measurements  
The fluorescence emission spectra of M-AMF-DOTA(Nd), M-AMF-DOTA, 
 Avidin-AMF-DOTA(Nd), and 4AMF-DOTA(Nd) (10 M) were measured in 10 
mM Tris-HCl buffer (pH 8.0) at 25 oC, following excitation at 488 nm.  
 
UV-Visible Absorption Spectral Measurements  
The absorption spectral changes of AMF-DOTA(Nd), M-AMF-DOTA and 
M-AMF-DOTA(Nd) (10 M) in 10 mM Tris-HCl buffer (pH 8.0) at 25 oC were 
determined. 
 
Quantum Yield Analysis  
Quantum yield analyses of M-AMF-DOTA(Nd) and 4AMF-DOTA(Nd) were 
measured by a previously reported method [13] in 10 mM Tris-HCl buffer 
(pH 8.0) at 25 oC, following excitation at 488 nm and emission at 880 nm.  
The reference compound, [Yb(Tropolonate)4], was measured at 380 nm 
excitation and 975 nm emission in 10 mM Tris-HCl buffer. The absorbance of 
the samples was adjusted to not exceed 0.2 at the excitation wavelength. The 
wavelength dependence on excitation light intensity and the detection 
efficiency of emission light were as given from HORIBA Jobin Yvon Inc.  
 
Time-Delayed Fluorescence Spectral Measurement.  
The time-delayed fluorescence spectra of M-AMF-DOTA(Nd) (10 M) were 
measured in 10 mM Tris-HCl buffer (pH 8.0) at 25 oC, following excitation at 
488 nm. A delay time of 7 s and a gate time of 100 s were used. 
 
Fluorescence Lifetime Measurements.  
The fluorescence lifetime of M-AMF-DOTA(Nd) (10 M) in 10 mM Tris-HCl 
buffer (pH 8.0) at 25 oC was determined. The data, obtained by monitoring 
the emission intensity at 880 nm (ex = 488 nm), were collected at a 
resolution of 1 s and were fit to a single-exponential curve using the 
equation shown below (Eq. 1), where I0 and I are the fluorescence intensities 
at time t = 0 and time t, respectively, and  is the fluorescence emission 
lifetime. 
 I = I0exp(-t / ) (Eq. 1)  
 
Biotin competitive assay.  
[125I]-IBB ([125I]-(3-iodobenzoyl)norbiotinamide) was prepared as previously 
described[14]. [125I]-IBB (0.5 mCi/mL) 10 L, D-biotin (5, 50, 500, 1000 mM) 
100 L, and PBS 290 L were added to a microtube containing 100 L of 
Avidin-AMF-DOTA(Nd) (80 g/mL) or avidin (80 g/mL). The reaction was 
performed at 37 °C for 1 h. The reaction mixture was applied to an Amicon 
Microcon filter (Millipore) and centrifuged at 4 °C, 1467 x g for 30 min (Micro 
Cooling Centrifuge 1720, Kubota, Osaka, Japan). The radioactivities of the 
reactant and filtrate were then measured, and the binding rate was 
calculated. 
 
 Cellular Uptake Study of Avidin-AMF-DOTA(Nd) and Avidin-FITC 
C6 glioma cells were maintained at 37 oC in a humidified atmosphere 
containing 5% CO2 in Dulbecco's modified eagle medium (DMEM) and 10% 
fetal bovine serum. Avidin-AMF-DOTA(Nd) or avidin conjugated to 
fluorescein isothiocyanate (Avidin-FITC) (50 g/mL in DMEM, 1.0 mL) were 
added to C6 glioma cells (1 x 105 cells/dish) and incubated for 1, 3, or 6 h. 
After incubation, the cells were twice washed with PBS(-), and then treated 
with trypsin to release them from the dish. Fluorescence levels were 
measured using a flow cytometer. Fluorescence intensities were normalized 
for quantum yield ( = 0.21 and 0.60 for Avidin-AMF-DOTA(Nd) and 
Avidin-FITC, respectively) and the number of labeling agents (2.5 and 4.0 for 




4-(Chloromethylamide)fluorescein (4AMF-Cl) [5] and radiolabeled IBB 
([125I]-IBB) [14] were prepared as previously described. 
 
 N-tert-buthoxycarbonyl-2-(2-chloroacetoamide)-aminoethane (Boc-Et-Cl).  
To a CHCl3 solution (100 mL) of N-(tert-buthoxycarbonyl)-1,2-diaminoethane 
(1.60 g, 10 mmol) and Et3N (10.1 g, 100 mmol) was slowly added ClCH2COCl 
(1.13 g, 10 mmol) in CHCl3 solution (20 mL) at 0 oC. The solution was stirred 
for 3 h and then evaporated to remove the solvent. The black-yellow residue 
was purified by silica gel column chromatography to obtain Boc-Et-Cl as a 
pale yellow powder (2.0 g, 8.5 mmol, 85%) 
LR-MS(ESI, neg.) m/z found 237 ([M+H]+), calcd. 237 
HR-MS (FAB, pos.) m/z found 237.0928, calcd. 237.0928 (C9H18ClN2O3) 
1H-NMR (400 MHz, CDCl3)  4.83 (2H, s), 3.46 (2H, t, J = 7.3 Hz), 3.25 (2H, t, 
J = 7.3 Hz), 1.45 (9H, s) 
 
1,4,7-tris(2-(tert-butoxycarbonyl)-2-amino-ethylamidemethyl)- 
1,4,7,10-tetraazacyclododecane ((BocEt)3DOTA).  
To a dry MeCN solution (50 mL) of 1,4,7,10-tetraazacyclododecane 
tetrahydrochloride (cyclen 4HCl)  (318 mg, 1.0 mmol), iPr2EtN (1.3 g, 10.0 
mmol) was added, and the reaction was stirred for 5 min at 40 oC under 
anaerobic conditions. Then Boc-Et-Cl (708 mg, 3 mmol) in dry MeCN 
solution (10 mL) was slowly added to the suspension. After stirring for 9 h at 
80 oC, the solution was evaporated to remove the solvent. The pale yellow 
residue was purified by silica gel column chromatography to obtain 
(BocEt)3DOTA as a white powder (320 mg, 0.4 mmol, 41%) 
LR-MS(ESI, neg.) m/z found 774 ([M+H]+), calcd. 774 
HR-MS (FAB, pos.) m/z found 773.5171 calcd. 773.5171 (C32H62N10O9) 




A dry DMF solution (10 mL) of (BocEt)3DOTA  (150 mg, 0.2 mmol) and 
K2CO3 (0.7 g, 5.0 mmol) was stirred for 5 min at 80 oC under anaerobic 
conditions. To the solution was slowly added 4-AMF-Cl (85 mg, 0.2 mmol) in 
 dry DMF solution (10 mL). After stirring for 7 h at 80 oC, the solution was 
evaporated to remove the solvent. The resulting residue was redissolved in a 
minimum amount of MeOH, the solution was poured into Et2O (20 mL), and 
the resulting residue was washed three times with Et2O by decantation. The 
powder was dried under vacuum to obtain AMF-(BocEt)3DOTA (139 mg, 0.14 
mmol, 60%) as a red powder. 
LR-MS(ESI, pos.) m/z found 1161 ([M+H]+), calcd. 1161 
HR-MS (FAB, pos.) m/z found 1160.5914 calcd. 1151.5914 (C57H82N11O15) 
1H-NMR (400 MHz, CD3OD)  8.38 (1H, s), 7.91 (1H, d, J = 7.3 Hz), 6.62 (3H, 




10-tetraazacyclododecane (AMF-(H2NEt)3DOTA).  
TFA (2.0 mL) was slowly added to a MeOH solution of AMF-(BocEt)3DOTA 
(116 mg, 0.1 mmol) at 0 oC. The solution was stirred for 10 min, and the 
mixture was evaporated to remove the solvent. The resulting residue was 
redissolved in a minimum amount of MeOH and evaporated. This procedure 
was repeated three times. The resulting powder was dried under vacuum to 
obtain AMF-(H2NEt)3DOTA (85 mg, 0.1 mmol, 99%) as an orange powder. 
LR-MS(ESI, pos.) m/z found 860 ([M+H]+), calcd. 860 
HR-MS (FAB, pos.) m/z found 860.4341 calcd. 860.4341 (C42H58N11O9) 
1H-NMR (400 MHz, CD3OD)  8.38 (1H, s), 7.91 (1H, d, J = 7.3 Hz), 6.62 (3H, 





To a dry DMF solution (10 mL) of AMF-(H2NEt)3DOTA (85 mg, 0.1 mmol) 
and Et3N (100 mg, 1.0 mmol) was added 
N-succinimidyl-3-maleimidepropionate (26 mg, 0.1 mmol), and the reaction 
 was stirred for 1 h at room temperature under anaerobic conditions. The 
solution was evaporated to remove the solvent. The resulting residue was 
redissolved in a minimum amount of MeOH. The solution was poured in 
Et2O (5 mL), and the resulting residue was washed three times with Et2O by 
decantation. The powder was dried under vacuum to obtain M-AMF-DOTA 
(55 mg, 0.05 mmol, 55%) as a red powder. 
LR-MS(ESI, neg.) m/z found 504 ([M-2H]2-), calcd. 504 
HR-MS (FAB, neg.) m/z found 1009.4610 calcd. 1009.4610 (C49H61N12O12) 
1H-NMR (400 MHz, CD3OD)  8.38 (1H, s), 7.91 (1H, d, J = 7.3 Hz), 6.62 (3H, 
m), 6.52 (2H, s), 6.92 (2H, d, J = 7.3 Hz), 6.44 (2H, dd, J = 1.9, 8.7 Hz), 
3.51-2.43 (40H, m) 
 
M-AMF-DOTA(Nd).  
To an EtOH solution (10 mL) of M-AMF-DOTA (10.1 mg, 10 mol) was added 
NdCl3 6H2O (3.6 mg, 10 mol). After stirring for 1 h at room temperature in 
the dark, the reaction mixture was filtered. The filtrate was evaporated and 
dried in vacuo to obtain M-AMF-DOTA(Nd) (10.4 mg, 9.0 mol, 90%) as a red 
powder. 
LR-MS (ESI, pos.) m/z found 576 ([M-H]2+), calcd. 576 
HR-MS (FAB, pos.) m/z found 1150.3531 calcd. 1150.3531 (C49H60N12NdO12) 
  
Avidin-AMF-DOTA(Nd) 
To avidin (1.0 mg, 15 nmol) in borate buffer (0.16 M with 2 mM EDTA, 100 
L) was added 2-iminothiolane (255 g, 185 nmol) in borate buffer (0.16 M 
with 2 mM EDTA, 25.5 L). After incubation at room temperature for 1h, 
dithiothreitol (30.8 g, 2.0 mol) in H2O (2.0 L) was added to the reaction 
mixture, and the reaction was allowed to stand for 15 min. After purification 
of the thiolated avidin by spin-column (Sephadex G50、GE healthcare UK 
Ltd.), a solution of PBS (0.1 M, pH 7.4, 172 L) containing 
M-AMF-DOTA(Nd) (1.7 mg, 1.5 mol) was added. The mixture was 
incubated at 37 oC for 1h in the dark. After incubation, N-ethyl maleimide 
 (40 g, 32 nmol) in DMSO (4.0 L) was added to cap unreacted thiols and the 
reaction was further incubated at room temperature for 30 min in the dark. 
After size-exclusion filtration twice with a PD-10 column (17-0851-01, GE 
Healthcare UK Ltd.) using 0.1 M PBS (pH 7.4), Avidin-AMF-DOTA(Nd) was 
obtained. 
The fluorescence spectrum of Avidin-AMF-DOTA(Nd) was measured by 
Fluorolog-3. The progress of the labeling reaction was confirmed by 
electrophoresis. Avidin-AMF-DOTA(Nd) and Avidin-AMF-DOTA were 
denatured in PBS by heating at 100 oC for 5 min. Then samples (10 L in 
each well) were separated by one-dimensional denaturing sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with a 5% to 20% 
gradient polyacrylamide gel (ePAGEL E-T520L, ATTO). A standard marker 
(Precision Plus ProteinTM Standards, BIO-RAD) was used as a protein 
molecular weight marker. After electrophoresis using the AE-8155 myPower-
Ⅱ 500 (ATTO) at 400 V, 20 mA for 70 min, the gel was stained with 
Coomassie Brilliant Blue R250 (CBB) to visualize the proteins.  
The number of thiols introduced per avidin was calculated by the following 
method: 4,4’-dithiodipyridine (22 g in 0.1 M PBS (pH 7.4, 20 L)) was added 
to thiolated avidin (85 g in 0.1 M PBS (pH 7.4, 500 L)), and the reaction 
was incubated at 30 oC for 30 min. After incubation, the absorbances of the 
reaction mixture at 280 nm and 324 nm were measured to calculate the 
number of thiols ( =113,900, 7,060 for avidin and thiol, respectively) using 
the equation below (Eq. 2).  





The number of M-AMF-DOTA(Nd) and M-AMF-DOTA per avidin were 
calculated by the equation below (Eq. 3) using the absorbances measured at 
280 and 488 nm of Avidin-AMF-DOTA(Nd) or Avidin-AMF-DOTA ( =113,900, 
18,000 and 18,000 L/(M*cm) for avidin, AMF-DOTA(Nd) and AMF-DOTA, 
respectively). 







To avidin (1.1 g, 17 nmol) in 20 mM Na2HPO4 (aq) (112 mL) was added 
FITC-I (126 g, 322 nmol) in DMSO (12.6 L). The mixture was incubated at 
room temperature for 1 h in the dark. After incubation, the mixture was 
purified by size-exclusion filtration with a PD-10 column (17-0851-01, GE 
Healthcare UK Ltd.) using 0.1 M PBS (pH 7.4) to obtain Avidin-FITC. 
The fluorescence of Avidin-FITC was measured by Fluorolog-3. SDS-PAGE 
and CBB staining of Avidin-FITC were performed by the same methods as 
for Avidin-AMF-DOTA. The number of FITC groups introduced onto avidin 
was calculated by the same method as for Avidin-AMF-DOTA ( =113,900 
and 80,000 L/(M*cm) for avidin and FITC (488 nm), respectively). 
 Results 
Synthesis and Characterization of M-AMF-DOTA(Nd) 
M-AMF-DOTA was synthesized from 4-amino-fluorescein and cyclen in 
six steps as shown in Scheme 1. The overall yield from 4-aminofluorescein 
was 24%. M-AMF-DOTA(Nd) was easily synthesized in 90% yield by stirring 
M-AMF-DOTA and NdCl3 in MeOH.  
In the IR spectra, amide-I absorptions were observed at 1558 cm-1 for 
M-AMF-DOTA and 1571 cm-1 for M-AMF-DOTA(Nd), and amide-II 
absorptions were found at 1635 cm-1 for M-AMF-DOTA and 1651 cm-1 for 
M-AMF-DOTA(Nd) (data not shown).  
The UV-vis absorption spectra of M-AMF-DOTA(Nd), M-AMF-DOTA and 
4AMF-DOTA(Nd) in buffer are shown in Figure 1A. Each spectrum shows 
the same strong absorption peak at 490 nm. 
The emission spectra of M-AMF-DOTA(Nd), M-AMF-DOTA and 
4AMF-DOTA(Nd) in buffer are shown in Figure 1B. Typical characteristic 
peaks at 880 nm and 900 nm were detected in the M-AMF-DOTA(Nd) and 
4AMF-DOTA(Nd) spectra (ex = 488 nm). In contrast, characteristic 
fluorescence peaks were not detected for M-AMF-DOTA under the same 
conditions. The 880 nm and 900 nm emission signals for M-AMF-DOTA(Nd) 
were slightly stronger than for 4AMF-DOTA(Nd). The quantum yields of 
M-AMF-DOTA(Nd) and 4AMF-DOTA(Nd) were calculated to be 1.2 x 10-5 
and 4.5 x 10-6, respectively.  
The excitation spectra of M-AMF-DOTA(Nd), M-AMF-DOTA and 
4AMF-DOTA(Nd) in buffer are shown in Figure 1C (em = 880 nm for 
M-AMF-DOTA(Nd) and 4AMF-DOTA(Nd) or 515 nm for M-AMF-DOTA). 
Each spectrum shows the same excitation peak at 490 nm. 
 
Long-lived fluorescence Measurement of M-AMF-DOTA(Nd).  
Time-resolved fluorescence (TRF) measurements of M-AMF-DOTA(Nd) 
are shown in Figure 2. Although a tailing fluorescence signal from the 
fluorescein moiety was detected below 850 nm in addition to the fluorescence 
 from Nd at 880 and 900 nm in the emission spectrum without TRF 
measurement, the fluorescence from fluorescein was not observed in the 
emission spectrum with TRF measurement. Furthermore, we calculated the 
lifetime of Nd ion fluorescence using the equation described in the 
Experimental section. The calculated lifetime was 2.3 s for the 880 nm 
fluorescence. 
 
Synthesis and Characterization of Avidin-AMF-DOTA(Nd) 
The number of AMF-DOTA(Nd) and AMF-DOTA per avidin molecule were 
approximately 2.5 and 5.0, respectively.  
In the SDS-PAGE analysis of purified Avidin-AMF-DOTA(Nd), the avidin  
mono-subunit (17kDa) band was clearly observed (Figure 3). This band 
exhibited fluorescence in the 548~630 nm region from 302 nm excitation. The 
emission spectra of aqueous solutions of Avidin-AMF-DOTA(Nd) and 
M-AMF-DOTA(Nd) are shown in Figure 4. Typical characteristic peaks, the 
same as for M-AMF-DOTA(Nd), at 880 nm and 900 nm were detected in the 
Avidin-AMF-DOTA(Nd) spectrum (ex = 488 nm).  
 
Biotin Binding Assay of Avidin-AMF-DOTA(Nd) 
The binding ability of Avidin-AMF-DOTA(Nd) to D-biotin was estimated 
by a displacement assay in comparison with avidin (Figure 5). The binding of 
Avidin-AMF-DOTA(Nd) toward radiolabeled biotin was inhibited by D-biotin 
in a dose-dependent manner. Avidin-AMF-DOTA(Nd) and avidin showed 
similar displacement curves.  
 
Cellular Uptake Study of Avidin-AMF-DOTA(Nd) 
Figure 6 shows the normalized fluorescence intensity of C6 glioma cells 
incubated with Avidin-AMF-DOTA(Nd) and Avidin-FITC. In the cellular 
uptake study, Avidin-AMF-DOTA(Nd) and Avidin-FITC displayed similar 
time-dependent increases in fluorescence intensity after normalization by 
quantum yield and number of labeling agents. Cellular appearance did not 
 change during the incubation. 
 
 Discussion 
There are some requirements that an ideal fluorescent labeling agent 
should fulfill. First, the label needs to emit fluorescence in a region that does 
not overlap with other light derived from the excitation or other compounds 
in test tubes, solutions, organs, or cells [15, 16]. A non-desired overlap could 
lead to a decrease in the signal-to-noise ratio. Second, fluorescence properties 
should not be changed by conjugation with a functional molecule for an 
accurate evaluation in subsequent studies. A change in the emission 
wavelength after conjugation would make interpretation of the data complex. 
Third, the ideal labeling agent should be able to label various compounds in 
an easy, quantifiable operation. Lastly, the fluorescent agent should not 
affect the chemical, physical, and biological features of the labeled compound 
after conjugation. The results obtained in this study indicate that 
M-AMF-DOTA(Nd) fulfilled all of the above requirements. 
 
M-AMF-DOTA was easily synthesized by standard methods. For the 
introduction of maleimide to M-AMF-DOTA by amidation (scheme 1, step f), 
the concentration of the reactants was very important. For the reaction 
conducted at a 10 mM concentration, only the 7-position amide 
M-AMF-DOTA was isolated; 4- and 10-position amide isomers were not 
observed. However, for reactions conducted at concentrations of 20~50 mM, 
4- or 10-position isomers and di-maleimide products were observed. 
M-AMF-DOTA(Nd) displayed characteristic emission peaks at 880 nm and 
900 nm (Figure 1B, ex = 488 nm) which can be assigned to a typical Nd 4F3/2 
to 4I9/2 transition, the same as 4AMF-DOTA(Nd)[5]. The quantum yield of 
M-AMF-DOTA(Nd) was approximately 2.5 times higher than that of 
4AMF-DOTA(Nd). This might be caused by the DOTA modification, 
aminoethylation of the carboxylic acid, which hinders the approach of 
fluorescent quenchers (H2O etc.) to the Nd ion in M-AMF-DOTA(Nd). In 
addition, the fluorescence lifetime of 2.3 s for the Nd complex was in 
agreement with previous reports [17, 18]. Although the fluorescence of 
 fluorescein and the Nd ion were observed without TRF measurements, 
fluorescein fluorescence was not observed in the emission spectra with TRF 
measurement resulting in extraction of only fluorescence from Nd. Therefore, 
TRF measurement is a potentially useful method for compounds labeled by 
M-AMF-DOTA(Nd). 
UV-vis spectra of buffer solutions of M-AMF-DOTA(Nd), M-AMF-DOTA 
and 4AMF-DOTA(Nd) showed the same absorption shape assigned to 
fluorescein absorption. This result suggests that the modification of DOTA 
and the chelation of the Nd ion to DOTA derivatives have no effect on the 
energy level of the fluorescein moiety. The excitation spectra of 
M-AMF-DOTA(Nd) (em = 880 nm) and M-AMF-DOTA (em = 515 nm) showed 
much the same features (Figure 1C). Thus, the supposition that the 
fluorescence of M-AMF-DOTA(Nd) at 880 ~ 900 nm is derived from the 
transfer of energy from an excited fluorescein moiety, the same as in the case 
of 4AMF-DOTA(Nd) [5], is supported by the data. 
 
NIR fluorescence analysis is particularly suited to living organisms 
because they contain few fluorescent compounds in the NIR region (700 
~1000 nm) while there are many naturally occurring fluorescent compounds 
in the visible region, such as fluorite (400 ~ 600 nm)[19], anthracene (400 
nm), chlorophyll (680 nm)[20], NAD(P)H (450 nm)[21] and flavin (520 
nm)[22]. Thus, NIR fluorescent dyes are recognized to be useful for 
fluorescent analysis [23-25]. In addition, fluorescence from lanthanides has a 
significant advantage in that the wavelength is constant with changes in 
environmental factors (solvent, pH, etc,)[6]. This is derived from the 
mechanism of lanthanide fluorescence where the 4f orbital responsible for 
fluorescence is located inside the 5s and 5d orbitals, which protect the 
fluorescence from environmental effects. A very large Stoke’s shift for 
M-AMF-DOTA(Nd) (about 400 nm) is another advantage over most other 
organic fluorescent labels. This contributes to the easy separation of the 
emission signals from the excitation light by suitable optical filters. Although 
 to date there are few instruments with good imaging ability in the NIR 
region (especially 800 ~ 1200 nm), NIR fluorescent analysis using potential 
labeling agents such as M-AMF-DOTA(Nd) could be effective with the 
development of suitable imaging instruments.  
 
Thiolated avidin was easily labeled by M-AMF-DOTA(Nd). The number 
of AMF-DOTA(Nd) complexes per avidin was half that of AMF-DOTA under 
the same reaction conditions, which would seem to be caused by a difference 
in tertiary structure. It is well known that lanthanide-DOTA derivative 
complexes form cage-like structures [26-28]. Therefore, M-AMF-DOTA(Nd) is 
a more rigid and hindered structure compared with M-AMF-DOTA. Thus, 
the maleimide group of M-AMF-DOTA(Nd) as compared with M-AMF-DOTA 
would have less chance of approaching a thiol group. It is remarkable that 
M-AMF-DOTA(Nd) is still reactive enough for the following studies as shown 
in Figure 3-6. 
Since maleimides readily react with thiols, we labeled avidin through 
Lys side chain NH2 groups via conversion to thiols by reaction with 
2-iminothiolane. This intermediate step is necessary because all Cys side 
chains in avidin form disulfide bonds [29] while most of the Lys side chains 
(about 6 or 7 per avidin monomer) are free on the protein surface [29]. The 
labeling reaction was easily completed, which demonstrates that the 
M-AMF-DOTA(Nd) fluorescent labeling agent could be linked with proteins 
through not only thiol but also primary amine side chains. 
 
In a displacement assay, both Avidin-AMF-DOTA(Nd) and naive avidin 
were inhibited by D-biotin in a similar dose-dependent manner (Figure 5). 
This result suggests that the conjugation did not affect the recognition 
ability of avidin with D-biotin. Another biological characteristic of avidin is 
its internalization into tumor cells after recognition by lectins expressed on 
the tumor cell surface [30, 31]. The flow cytometry analysis of C6 glioma cells 
after incubation with Avidin-AMF-DOTA(Nd) or Avidin-FITC displayed 
 similar time-dependent increases in fluorescence intensity (Figure 6). 
Avidin-FITC has been used as an effective fluorescent labeled avidin in 
evaluating receptor mediated endocytosis in in vitro studies [32]. Although 
FITC is a very good labeling agent that emits bright ( = 0.60) fluorescence, 
it is not applicable for in vivo studies because of its visible (em = 515 nm) 
fluorescence. On the other hand, M-AMF-DOTA(Nd) is potentially usable for 
in vivo fluorescence imaging because of its NIR fluorescence as described 
above.  
For the spacer between the fluorophore and avidin, the results indicate 
that conjugation did not disrupt the fluorescent properties (Figure 4) or the 
distinctive binding features of avidin (Figures 5 and 6) and support the 
validity of the spacer selection. 
 
Although the data are not shown, M-AMF-DOTA(Nd) could not be used 
for fluorescent analysis under strongly acidic conditions (lower than pH 5) 
because the fluorescent signal disappeared, a property that depends on the 
particular fluorescein used as the antenna moiety of M-AMF-DOTA(Nd) [5, 
6]. We recently reported another NIR fluorescent compound with a large 
Stoke’s shift, PAN-DOTA(Yb), had constant fluorescent features over a wide 
pH range (3~11) [6]. Application of the findings obtained in this study to 
PAN-DOTA(Yb) may lead to the development of an even more useful NIR 
fluorescent labeling agent in the future. 
 Conclusion 
 
In this study, we synthesized an M-AMF-DOTA(Nd) derivative that 
includes maleimide linker and NIR fluorophore moieties as a new labeling 
agent with a large Stoke’s shift. M-AMF-DOTA(Nd) was used to easily label 
an avidin molecule through Lys side chains without loss of functional 
characteristics of avidin or fluorescent features of the labeling agent. The 
results indicate that M-AMF-DOTA(Nd) is a potential labeling agent for 
routine fluorescence analysis with several favorable properties including 
NIR emission, constant fluorescence unaffected by conjugation, good labeling 
ability for amines and thiols, and no effect on the chemistry or biology of the 
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Scheme 1. Synthetic scheme of M-AMF-DOTA(Nd). Reagents and conditions: a) chloroacetyl chloride, 0 oC, 3 h, b) cyclen 
4HCl, iPr2EtN, 80 oC, 9 h, c) chloroacetyl chloride, 0 oC, 1 h, d) K2CO3, 80 oC, 7h, e) TFA, 0 oC, 10 min, f) 
N-succinimidyl-3-maleimidepropionate, Et3N, room temperature, 1 h, g) NdCl3 6H2O 
  
Figure 1. Spectroscopy data for M-AMF-DOTA(Nd) (bold line), M-AMF-DOTA (solid line) and 4AMF-DOTA(Nd) (dotted 
line). (A) UV-vis absorption spectra (B) Emission spectra (ex = 488 nm). (C) Excitation spectra (em = 880 nm for 
M-AMF-DOTA(Nd) and 4AMF-DOTA(Nd), 515 nm for M-AMF-DOTA). 
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Figure 4. Fluorescence spectra of Avidin-AMF-DOTA(Nd) (bold solid line) and M-AMF-DOTA(Nd) (solid line). Each 
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Figure 5. Displacement assay of Avidin-AMF-DOTA(Nd) (solid line) (or avidin (dotted line)), [125I]-IBB and various 
concentrations of D-biotin.  
  
Figure 6. Normalized fluorescence intensity of C6 glioma cells incubated with Avidin-AMF-DOTA(Nd) (left) or 
Avidin-FITC (right). 
  
